Skip to main content

Table 3 Panobinostat trials reported in 2009 and 2010

From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Combination therapy

Type of cancer

Phase

N

Outcome (most relevant findings)

Literature

None

Relapsed/refractory Hodgkin lymphoma

II

53

1CR, 10PR, 31SD

Younes et al. (2009)a

None

Myelofibrosis (MF)

I

176 (thereof n = 13 with MF)

MF:1PR, 3CI

DeAngelo et al. (2009)a

None

Myelofibrosis

I

8

2CI; 4SD

Mascarenhas et al. (2009)a

Lenalidomid, Dexamethasone

Multiple myeloma

I

22

5/10 mg Panobinostat: regarded as safe

Spencer et al. (2009)a

Bortezomib

Relapsed multiple myeloma

I

28

64% Response: 4CR; 10PR; 4 minor responses

San-Miguel et al. (2009)a

Melphalan

Multiple myeloma

I

12

1CR; 3PR; 4SD

Berenson et al. (2009a, b)a

Imatinib

Chronic myeloic leukemia

I

n = 5

MTD to be determined

Bhatia et al. (2009)a

Docetaxel

Castration-resistant prostate cancer

I

n = 16

no effects as single agents; 5 patients with PSA decline >50%

Rathkopf et al. (2010)

Trastuzumab

HER-2 positive metastatic breast cancer

I

n = 18

 

Conte et al. (2009)

  1. aMeeting report abstract